Advances in the treatment of porphyria cutanea tarda. Effectiveness of slow subcutaneous desferrioxamine infusion.
Liver
; 4(4): 280-4, 1984 Aug.
Article
in En
| MEDLINE
| ID: mdl-6482687
ABSTRACT
The authors present the results of long-term subcutaneous desferrioxamine (DFX) infusion in 16 porphyria cutanea tarda (PCT) patients who cannot undergo repeated phlebotomies because of severe liver damage, haemolytic anemia, cardiovascular impairment or pulmonary and bone tuberculosis. They employed an automatic, portable syringe pump for subcutaneous infusion (8-10 h) to overcome the short half-life of the drug. Photodynamic cutaneous lesions and hyperpigmentation quickly disappeared (2-3 months). Uroporphyrin excretion sharply decreased and normalized within 3-12 months. Also, serum iron and ferritin, as well as liver function, showed a significant improvement. The authors therefore propose subcutaneous DFX therapy in PCT treatment when phlebotomy is contraindicated.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Porphyrias
/
Skin Diseases
/
Deferoxamine
Limits:
Adult
/
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
Liver
Year:
1984
Document type:
Article